# US 2015/0148426 A1 · Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148426 A1
- Document ID: US20150148426A1
- Status: Published application
- Kind: A1
- Application number: 14/603,661
- Filed: 2015-01-23
- Published: 2015-05-28
- Earliest claimed: 2011-04-19
- Assignees: Integrative Research Laboratories Sweden AB
- Inventors: Clas SONESSON; Jonas KARLSSON; Peder SVENSSON
- Web page: https://patentgrep.com/patent/US20150148426A1

## CPC

- C07C 317/22: with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 211/22: by oxygen atoms
- C07D 295/088: to an acyclic saturated chain
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07C 2601/02: with a three-membered ring
- C07C 2601/04: with a four-membered ring
- C07C 2601/08: the ring being saturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

## Claims

### Claim 1

A phenoxy-ethyl-amine derivative, wherein the phenoxy-ethyl-amine derivative is N-[2-(3-fluoro-5-methylsulfonyl-phenoxy)ethyl]propan-1-amine, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The phenoxy-ethyl-amine derivative of claim 1, wherein the phenoxy-ethyl-amine derivative is a hydrochloric acid salt of N-[2-(3-fluoro-5-methylsulfonyl-phenoxy)ethyl]propan-1-amine.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the phenoxy-ethyl-amine derivative of claim 1, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient, or diluent.

### Claim 4 (depends on 1)

A method of treatment of a disease or a disorder or a condition of a patient, which disorder, disease or condition is selected from the group consisting of psychosis, schizophrenia, schizophreniform disorder, bipolar disorder, anxiety disorder, depression, obsessive-compulsive disease, dementia, age-related cognitive impairment, Autism spectrum disorders, attention deficit hyperactivity disorder (ADHD), Gilles de la Tourette's syndrome, eating disorder, Parkinson's disease, parkinsonian syndrome, L-3,4-dihydroxyphenylalanine (L-DOPA) induced dyskinesia, Tardive dyskinesia, dystonia, Huntington's disease, and Alzheimer's disease, which method comprises the step of administering to such as patient in need thereof a therapeutically effective amount of the phenoxy-ethyl-amine derivative of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the disease or the disorder or the condition is selected from the group consisting of schizophrenia, L-DOPA induced dyskinesia, and Huntington's disease.

### Claim 6 (depends on 4)

The method of claim 4, wherein the disease or the disorder or the condition is L-DOPA induced dyskinesia.

### Claim 7 (depends on 1)

A method of treatment of psychotic disorder of a patient, which method comprises the step of administering to such a patient in need thereof a therapeutically effective amount of the phenoxy-ethyl-amine derivative of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 8

A phenoxy-ethyl-amine derivative, wherein the phenoxy-ethyl-amine derivative is N-[2-(3-fluoro-5-methylsulfonyl-phenoxy)ethyl]butan-1-amine, or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 8)

The phenoxy-ethyl-amine derivative of claim 8, wherein the phenoxy-ethyl-amine derivative is a hydrochloric acid salt of N-[2-(3-fluoro-5-methylsulfonyl-phenoxy)ethyl]butan-1-amine.

### Claim 10 (depends on 8)

A pharmaceutical composition comprising a therapeutically effective amount of the phenoxy-ethyl-amine derivative of claim 8, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient, or diluent.

### Claim 11 (depends on 8)

A method of treatment of a disease or a disorder or a condition of a patient, which disorder, disease or condition is selected from the group consisting of psychosis, schizophrenia, schizophreniform disorder, bipolar disorder, anxiety disorder, depression, obsessive-compulsive disease, dementia, age-related cognitive impairment, Autism spectrum disorders, ADHD, Gilles de la Tourette's syndrome, eating disorder, Parkinson's disease, parkinsonian syndrome, L-DOPA induced dyskinesia, Tardive dyskinesia, dystonia, Huntington's disease, and Alzheimer's disease, which method comprises the step of administering to such a patient in need thereof a therapeutically effective amount of the phenoxy-ethyl-amine derivative of claim 8, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the disease or the disorder or the condition is selected from the group consisting of schizophrenia, L-DOPA induced dyskinesia, and Huntington's disease.

### Claim 13 (depends on 11)

The method of claim 11, wherein the disease or the disorder or the condition is L-DOPA induced dyskinesia.

### Claim 14 (depends on 8)

A method of treatment of psychotic disorder of a patient, which method comprises the step of administering to such a patient in need thereof a therapeutically effective amount of the phenoxy-ethyl-amine derivative of claim 8, or a pharmaceutically acceptable salt thereof.

### Claim 15

A phenoxy-ethyl-amine derivative, wherein the phenoxy-ethyl-amine derivative is N-ethyl-2-(3-fluoro-5-methylsulfonyl-phenoxy)ethanamine, or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The phenoxy-ethyl-amine derivative of claim 15, wherein the phenoxy-ethyl-amine derivative is a hydrochloric acid salt of N-ethyl-2-(3-fluoro-5-methylsulfonyl-phenoxy)ethanamine.

### Claim 17 (depends on 15)

A pharmaceutical composition comprising a therapeutically effective amount of the phenoxy-ethyl-amine derivative of claim 15, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient, or diluent.

### Claim 18 (depends on 15)

A method of treatment of a disease or a disorder or a condition of a patient, which disorder, disease or condition is selected from the group consisting of psychosis, schizophrenia, schizophreniform disorder, bipolar disorder, anxiety disorder, depression, obsessive-compulsive disease, dementia, age-related cognitive impairment, Autism spectrum disorders, ADHD, Gilles de la Tourette's syndrome, eating disorder, Parkinson's disease, parkinsonian syndrome, L-DOPA induced dyskinesia, Tardive dyskinesia, dystonia, Huntington's disease, and Alzheimer's disease, which method comprises the step of administering to such a patient in need thereof a therapeutically effective amount of the phenoxy-ethyl-amine derivative of claim 15, or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the disease or the disorder or the condition is selected from the group consisting of schizophrenia, L-DOPA induced dyskinesia, and Huntington's disease.

### Claim 20 (depends on 18)

The method of claim 18, wherein the disease or the disorder or the condition is L-DOPA induced dyskinesia.
